Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. (Q53528762)

15 May 2018

title

Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. (English)

1 reference

15 May 2018

main subject

myelodysplastic syndrome

1 reference

8

1 reference

15 May 2018

Hans Joachim Deeg

7

object named as

H J Deeg

1 reference

15 May 2018

9

M E D Flowers

1 reference

15 May 2018

author name string

P V Campregher

1

1 reference

15 May 2018

T Gooley

2

1 reference

15 May 2018

B L Scott

3

1 reference

15 May 2018

C Moravec

4

1 reference

15 May 2018

B Sandmaier

5

1 reference

15 May 2018

P J Martin

6

1 reference

15 May 2018

language of work or name

English

0 references

publication date

10 September 2007

1 reference

15 May 2018

Bone Marrow Transplantation

published in

1 reference

15 May 2018

volume

40

1 reference

15 May 2018

page(s)

965-971

1 reference

15 May 2018

issue

10

1 reference

15 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705840

exact match

0 references

cites work

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Graft-versus-leukemia reactions in allogeneic chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Wo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Acute myeloid leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Myelodysplastic syndromes: the complexity of stem-cell diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Adoptive transfer of allogeneic antigen-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

7 January 2021

Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

7 January 2021

Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

7 January 2021

Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

7 January 2021

Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

7 January 2021

Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

7 January 2021

The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

7 January 2021

Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

7 January 2021

Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705840

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705840

1 reference

15 May 2018

Dimensions Publication ID

0 references

1 reference

15 May 2018